Drugs / Pneumococcal 13-valent Conjugate Vaccine
Pneumococcal 13-valent Conjugate Vaccine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03942328 | Sep 2019 → May 2030 expected | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02518555 | Jan 2016 → Dec 2025 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Jennifer Woyach | Completed | No outcome recorded |
| Phase 2 | NCT02309515 | Jun 2015 → Apr 2017 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02049138 | Jan 2014 → Jul 2021 | rheumatoid arthritis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01654263 | Oct 2012 → Aug 2015 | pneumococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03630705 | Oct 2018 → Feb 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Comparator or background therapy8 trials | ||||||
| Phase 1/2 | NCT06647407 Background | Nov 2024 → May 2027 expected | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03035331 Background | Aug 2017 → Jan 2022 | T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +2 | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT04398706 Comparator | May 2020 → Aug 2023 | chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03691610 Background | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03673462 Background | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01214837 Background | Oct 2010 → Apr 2012 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT04535037 Background | May 2021 → Jul 2022 | diphtheria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT04080531 Background | Oct 2019 → May 2021 | plasma cell neoplasm | Emory University | Completed | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal 13-valent Conjugate Vaccine | “Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae...” NCT01214837 ↗ |
| Known as | PCV-13 | “PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age” NCT03673462 ↗2“Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine.” NCT01654263 ↗ “Pneumococcal 13-valent conjugate vaccine (PCV-13)” NCT02049138 ↗ |
| Known as | Prevnar | “pneumococcal 13-valent conjugate vaccine (Prevnar)” NCT03942328 ↗ |
| Known as | Prevnar 13 | “PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age” NCT03673462 ↗1“Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine.” NCT01654263 ↗ |
| Modality | Vaccine | “Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae...” NCT01214837 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular (IM) injection” NCT01654263 ↗ |